These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 23562090

  • 1. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
    Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group.
    Lancet; 2013 Jun 01; 381(9881):1905-15. PubMed ID: 23562090
    [Abstract] [Full Text] [Related]

  • 2. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group.
    Lancet Diabetes Endocrinol; 2021 Aug 01; 9(8):502-514. PubMed ID: 34214479
    [Abstract] [Full Text] [Related]

  • 3. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
    Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, START Study Team.
    Lancet Diabetes Endocrinol; 2013 Dec 01; 1(4):306-16. PubMed ID: 24622416
    [Abstract] [Full Text] [Related]

  • 4. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
    von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR, Anti-IL-21–liraglutide Study Group investigators and contributors.
    Lancet Diabetes Endocrinol; 2021 Apr 01; 9(4):212-224. PubMed ID: 33662334
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
    Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A.
    Lancet Diabetes Endocrinol; 2014 Sep 01; 2(9):710-8. PubMed ID: 24997559
    [Abstract] [Full Text] [Related]

  • 6. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
    Hensen J, Howard CP, Walter V, Thuren T.
    Diabetes Metab; 2013 Dec 01; 39(6):524-31. PubMed ID: 24075453
    [Abstract] [Full Text] [Related]

  • 7. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B, Bosteels C, De Leeuw E, Declercq J, Van Damme K, Delporte A, Demeyere B, Vermeersch S, Vuylsteke M, Willaert J, Bollé L, Vanbiervliet Y, Decuypere J, Libeer F, Vandecasteele S, Peene I, Lambrecht B.
    Trials; 2020 Jun 03; 21(1):468. PubMed ID: 32493441
    [Abstract] [Full Text] [Related]

  • 8. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
    Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG, Protégé Trial Investigators.
    Lancet; 2011 Aug 06; 378(9790):487-97. PubMed ID: 21719095
    [Abstract] [Full Text] [Related]

  • 9. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
    Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group.
    Lancet; 2011 Jul 30; 378(9789):412-9. PubMed ID: 21719096
    [Abstract] [Full Text] [Related]

  • 10. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
    Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, T1DAL Study Team.
    Lancet Diabetes Endocrinol; 2013 Dec 30; 1(4):284-94. PubMed ID: 24622414
    [Abstract] [Full Text] [Related]

  • 11. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.
    Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START Study Team.
    Diabetologia; 2016 Jun 30; 59(6):1153-61. PubMed ID: 27053235
    [Abstract] [Full Text] [Related]

  • 12. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, CANTOS Trial Group.
    Lancet; 2017 Oct 21; 390(10105):1833-1842. PubMed ID: 28855077
    [Abstract] [Full Text] [Related]

  • 13. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    Quattrin T, Haller MJ, Steck AK, Felner EI, Li Y, Xia Y, Leu JH, Zoka R, Hedrick JA, Rigby MR, Vercruysse F, T1GER Study Investigators.
    N Engl J Med; 2020 Nov 19; 383(21):2007-2017. PubMed ID: 33207093
    [Abstract] [Full Text] [Related]

  • 14. Interventions for reducing inflammation in familial Mediterranean fever.
    Yin X, Tian F, Wu B, Xu T.
    Cochrane Database Syst Rev; 2022 Mar 29; 3(3):CD010893. PubMed ID: 35349164
    [Abstract] [Full Text] [Related]

  • 15. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group.
    Lancet; 2011 Jul 23; 378(9788):319-27. PubMed ID: 21714999
    [Abstract] [Full Text] [Related]

  • 16. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).
    Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V.
    Ann Rheum Dis; 2011 May 23; 70(5):747-54. PubMed ID: 21173013
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC, CNTO1959PSA2001 Study Group.
    Lancet; 2018 Jun 02; 391(10136):2213-2224. PubMed ID: 29893222
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU.
    Lancet Diabetes Endocrinol; 2016 Mar 02; 4(3):221-232. PubMed ID: 26656289
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-1 inhibitors for acute gout.
    Sivera F, Wechalekar MD, Andrés M, Buchbinder R, Carmona L.
    Cochrane Database Syst Rev; 2014 Sep 01; 2014(9):CD009993. PubMed ID: 25177840
    [Abstract] [Full Text] [Related]

  • 20. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
    Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, Fantus IG, Hutton E, Armson AB, Lipscombe LL, Simmons D, Barrett JFR, Karanicolas PJ, Tobin S, McIntyre HD, Tian SY, Tomlinson G, Murphy KE, MiTy Collaborative Group.
    Lancet Diabetes Endocrinol; 2020 Oct 01; 8(10):834-844. PubMed ID: 32946820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.